Blood test could predict ovarian cancer relapse months early in BRCA patients

NCT ID NCT06588322

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times

Summary

This study looks at whether a simple blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA gene mutations who are taking a maintenance drug called Olaparib (with or without bevacizumab) after initial treatment. Researchers will collect 9 blood samples over 24 months to see if detecting these changes can predict disease progression earlier than standard scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chu de Limoges

    RECRUITING

    Limoges, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chu de Nimes

    RECRUITING

    Nîmes, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Angers

    RECRUITING

    Angers, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Saint-Herblain

    RECRUITING

    Saint-Herblain, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • IUCT-O

    RECRUITING

    Toulouse, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Bergonie

    RECRUITING

    Bordeaux, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.